BioCentury
ARTICLE | Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

July 17, 2018 10:27 PM UTC

Cellectar Biosciences Inc. (NASDAQ:CLRB) said a patient with advanced Waldenström's macroglobulinemia receiving CLR 131 in a Phase II trial achieved a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses as measured by CT scan 64 days after a second dose.

Prior to enrollment, the 67-year-old female patient received two lines of multidrug therapy and had achieved a best response of disease progression. The patient initially received a single dose of 25 mCi/m2 IV CLR 131 and achieved a partial response as measured by CT scan at day 52 post infusion. The patient was administered a second dose of CLR 131 on day 123...

BCIQ Company Profiles

Cellectar Biosciences Inc.